High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome

Background: Recent studies demonstrated low-grade inflammation in patients with irritable bowel syndrome (IBS). However, these studies have been relatively small and do not enable examination of this factor in different subtypes of IBS and the possibility of confounding effects of comorbidities that may be associated with inflammatory responses. Goals: To investigate the association between high-sensitive C-reactive protein (hs-CRP) and the diagnosis of IBS, IBS subtypes, symptoms’ severity, and IBS-associated comorbidities. Study: This cross-sectional study uses data from a large matched case-control study of IBS subjects and healthy controls (HC). hs-CRP levels were measured in all subjects. IBS diagnosis was determined by Rome III criteria, negative screening blood tests, and normal colonoscopy. Subjects were evaluated for IBS severity and associated pain and psychological comorbidities. Results: A total of 242 IBS patients and 244 HC were studied. Median hs-CRP levels in the IBS group were significantly higher than in HC (1.80; interquartile range, 0.7 to 4.04 mg/L vs. 1.20, interquartile range, 0.5 to 2.97 mg/L respectively, P<0.006). Levels were highest in IBS-D patients with greater disease severity. Hs-CRP levels mildly correlated with symptoms severity (r=0.169, P=0.009); this correlation was stronger for the IBS-D patients (r=0.27, P=0.006). IBS was a significant independent predictor (P=0.025) for higher hs-CRP levels, whereas other pain and psychological comorbidities were not. Conclusions: Given these observations of cross-sectional differences in hs-CRP between IBS subtypes and severity, independent of pain and comorbidities, more research is needed to explore a possible role of low-grade inflammation in the pathogenesis and/or clinical presentation of IBS.

[1]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[2]  Y. Ringel,et al.  Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[3]  P. Moayyedi,et al.  Peripheral mechanisms in irritable bowel syndrome. , 2013, The New England journal of medicine.

[4]  R. Sagar,et al.  Psychiatric, Somatic and Other Functional Gastrointestinal Disorders in Patients With Irritable Bowel Syndrome at a Tertiary Care Center , 2012, Journal of neurogastroenterology and motility.

[5]  K. Goh,et al.  Anxiety and depression in various functional gastrointestinal disorders: Do differences exist? , 2012, Journal of digestive diseases.

[6]  Qi-yang Huang,et al.  Subtypes of irritable bowel syndrome on Rome III criteria: A multicenter study , 2012, Journal of gastroenterology and hepatology.

[7]  A. Beekman,et al.  Association of depressive disorders, depression characteristics and antidepressant medication with inflammation , 2012, Translational Psychiatry.

[8]  Z. Halpern,et al.  Assessment of high‐sensitivity CRP as a marker of micro‐inflammation in irritable bowel syndrome , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[9]  Oliver Grundmann,et al.  Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health‐care practitioners , 2010, Journal of gastroenterology and hepatology.

[10]  N. Rezaei,et al.  T-Helper 1, T-Helper 2, and T-Regulatory Cytokines Gene Polymorphisms in Irritable Bowel Syndrome , 2010, Inflammation.

[11]  Hyojin Park,et al.  Increased Immunoendocrine Cells in Intestinal Mucosa of Postinfectious Irritable Bowel Syndrome Patients 3 Years after Acute Shigella Infection - An Observation in a Small Case Control Study , 2009, Yonsei medical journal.

[12]  J. Slaets,et al.  Is high-sensitive C-reactive protein a biomarker for functional somatic symptoms? A population-based study , 2009, Brain, Behavior, and Immunity.

[13]  L. Öhman,et al.  T-Cell Activation in Patients With Irritable Bowel Syndrome , 2009, The American Journal of Gastroenterology.

[14]  D. Drossman,et al.  Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar , 2009, Journal of clinical gastroenterology.

[15]  R. Spiller.  Irritable bowel syndrome: Bacteria and inflammation—Clinical relevance now , 2007, Current treatment options in gastroenterology.

[16]  Gerald Holtmann,et al.  Immune activation in patients with irritable bowel syndrome. , 2007, Gastroenterology.

[17]  G. O’Keefe,et al.  Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[19]  C. Ihlebæk,et al.  Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications , 2004, Alimentary pharmacology & therapeutics.

[20]  G. Barbara,et al.  New pathophysiological mechanisms in irritable bowel syndrome , 2004, Alimentary pharmacology & therapeutics.

[21]  T. Mach.  The brain-gut axis in irritable bowel syndrome--clinical aspects. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[22]  N. Read,et al.  Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome , 2003, Gut.

[23]  P. Whorwell,et al.  Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? , 2003, Gut.

[24]  B. Nyberg,et al.  Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. , 2002, Gastroenterology.

[25]  G. Barbara,et al.  A role for inflammation in irritable bowel syndrome? , 2002, Gut.

[26]  Wangxue Chen,et al.  Activation of the mucosal immune system in irritable bowel syndrome. , 2002, Gastroenterology.

[27]  W. Whitehead,et al.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? , 2002, Gastroenterology.

[28]  A. Poullis,et al.  A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders , 2002, European journal of gastroenterology & hepatology.

[29]  R. Spitzer,et al.  The PHQ-15: Validity of a New Measure for Evaluating the Severity of Somatic Symptoms , 2002, Psychosomatic medicine.

[30]  R. Spiller,et al.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acuteCampylobacter enteritis and in post-dysenteric irritable bowel syndrome , 2000, Gut.

[31]  C. O'Morain,et al.  Increased mast cells in the irritable bowel syndrome , 2000, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[32]  P. Whorwell,et al.  IL-10 and TGF-B genotypes in irritable bowel syndrome: Evidence to support an inflammatory component , 2000 .

[33]  G. Sturniolo,et al.  [Irritable bowel syndrome]. , 1988, Giornale di clinica medica.

[34]  N. Chaudhary,et al.  The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases. , 1962, The Quarterly journal of medicine.

[35]  L. Katz,et al.  Mast cells in inflammatory conditions of the gastrointestinal tract. , 1962, The American journal of gastroenterology.

[36]  N. Rezaei,et al.  Proinflammatory Cytokine Gene Polymorphisms in Irritable Bowel Syndrome , 2009, Journal of Clinical Immunology.

[37]  H. Verspaget,et al.  Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. , 2005, The American journal of gastroenterology.

[38]  D. Drossman,et al.  Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. , 1995, Digestive diseases and sciences.